Annual reportSep 2026
Sep 2026 · Shareholders meeting 3 Sep - Vasa Denticity issued FY26 annual report and AGM notice; AGM on September 29, 2026.
Source: Nse
Vasa Denticity Ltd. (DENTALKART)
SME CapPharma stocks · SME cap · NSE
Vasa Denticity Ltd. operates in Dental Products, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 03:31 pm ISTDetails
Quote21 Oct, 03:31 pm IST
Base fundamentals16 Oct 2026 · screener
Latest result16 Aug, 01:12 am IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags24 Apr 2026
Coverage12/14 · 86%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
75BullishSMA20 +10.5% / mo · MACD − · sector +4.9pp vs Nifty 500 (3M)
Stock trend: 59
Sector RS: 100
Sector 3M: -0.7% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
DENTALKARTD candles · FIT view+6.9%TODAY · PROVISIONALLatest price ₹440.00 on 2026-10-21
Today's candle is provisional from the latest intraday quote; completed-candle scans remain unchanged.
Bar
+0.0%
RSI
50
MACD hist
-3.34
52W pos
40%
2026-10-21O ₹440.00H ₹443.00L ₹436.00C ₹440.00Vol 4,750 shIntraday candle
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
DENTALKARTNifty PharmaNifty 500
- DENTALKART
- +4.7%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- +10.3 pp
Chart stats
19 Oct 2026- From 52W high
- -28.6%
- 52W range position
- 40%
- ATR (14)
- 5.8%
- Volume vs 20D
- 0.85x
- Avg traded value
- ₹0.6 Cr
- 20D price channel
- ₹400 - ₹500.1
₹616
₹322.5 - ₹616
₹25.5
Latest completed session
20-session average
50.5% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
Legacy · OVERVALUED14
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Excellent100
Revenue +37.4% · PAT +51.7% YoY
Technical
Bullish75
Price trend and sector-relative-strength timing.
Valuation
Legacy model-1603.9%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence54
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Excellent · 100/100Rev +37% YoY · PAT +52% YoY · margin expansion · +13% QoQ · operating leverage
Filed 30 Jun 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹83.1 Cr | +37.4% | +13.5% |
| EBITDA | ₹5.1 Cr | +66.4% | +1707.1% |
| Operating margin | 6.1% | +107 bps | +571 bps |
| PAT | ₹4.1 Cr | +51.7% | +224.0% |
| PAT margin | 4.9% | +46 bps | +316 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 69.40
- P/B
- 4.64
- EV/EBITDA
- 50.38
- Market Cap
- 806.00Cr
Profitability
- ROE
- 4.51%
- ROCE
- 6.95%
- ROA
- 5.58%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 21.11%
- EPS 5Y
- -9.82%
- Revenue 3Y
- -4.00%
- EPS 3Y
- -4.00%
Balance Sheet
- Debt/Equity
- 0.00
- Interest Coverage
- —
- Altman Z
- 9.18
- Book Value
- 100.00
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 0/5
- OCF
- -25.00 Cr
- EPS TTM
- 6.69
Shareholding
- Promoter Hold
- 60.19%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 48%
Financial History
Updated 20/10/2026
Revenue
₹ CrLatest: 277+14.9% vs prev
Net Profit
₹ CrLatest: 10.0-41.2% vs prev
Return on Equity
%Latest: 5.8-55.0% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term uptrend intact. RSI 50. Wait for confirmation.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 rising (~9.6% over last month) — short-term momentum positive.
- RSI(14) at 50 — falling, no extreme reading.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- 29% off 52W high · 36% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
51
RS percentile
Stage 2 UptrendNew S2
1M return
+4.7%
3M return
+4.7%
6M return
+15.2%
1Y return
-27.2%
RS 1D
-8
RS 20D
+13
Sector rank
#1
Industry rank
#17
Stage evidence
- Price is 8.9% above the 30-week proxy.
- The 50-DMA is above the 30-week proxy and its slope is rising +0.5%.
- Both 3-month and 6-month returns are positive.
50-DMA
price above
200-DMA
price above
S2 entered
19 Oct 2026
S2 age
1 trading session
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
261 observations
19 Oct 2026Value 73.26-4.29%
RS vs Nifty 50073
Valuation & peers
U-Score 14 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 14 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
OVERVALUED
Fundamental score breakdown
U band · OVERVALUEDValuation0/30
Growth5/25
Quality0/20
Balance Sheet8/15
Cash Flow0/10
Piotroski
4/9 (+1)
Penalties
0
Raw sum
14
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
14/100 · legacy band OVERVALUED
Positive drivers
- Balance sheet contributes 8/15 to the score.
- Growth contributes 5/25 to the score.
- Valuation contributes 0/30 to the score.
Main drags
- Fair-value margin of safety is negative at -1603.9%.
- Valuation is weaker at 0/30; verify the latest quarterly trend.
- Quality is weaker at 0/20; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
69.4
PB
4.6
EV/EBITDA
50.4
ROE
4.5%
ROCE
7.0%
FCF Yield
—
Debt/Equity
0.0
MoS
-1603.9%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
14
Previous: 14
Legacy U-Score band
OVERVALUED
Previous: OVERVALUED
Margin of safety
-1603.9%
Previous: -1603.9%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
16
16
16
16
16
16
14
14
14
14
14
14
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹122.69
-258.6% MoS
Growth-justified P/E
3.9
Growth-justified Value
₹25.82
-1603.9% MoS
PEG
—
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
LAXMIDENTL
Small
Laxmi Dental Limited
Healthcare Services
match 155
56
30.2
14.8%
+28%
FAIR VALUE
UNIHEALTH
SME
Unihealth Hospitals Ltd.
Healthcare Services
match 135
62
34.9
21.5%
+31%
UNDERVALUED
CHANDAN
SME
Chandan Healthcare Ltd.
Healthcare Services
match 134
58
22.2
19.8%
+50%
FAIR VALUE
QMSMEDI
SME
QMS Medical Allied Services Ltd.
Healthcare Services
match 133
32
33.4
10.4%
+29%
WATCHLIST
ZIMLAB
Small
Zim Laboratories Limited
Healthcare Services
match 133
17
200.0
1.6%
-6584%
OVERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Vasa Denticity Ltd. operates in Dental Products, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
54Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 13th percentile of the scored universe and 9th percentile within Pharma. Main check: cash conversion is weak at 28/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
13 docs text-extracted · 7 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
13th percentile
overall median 67 · Pharma: 9th pctile, median 70 · SME: 14th pctile, median 64
Evidence depth
Financial-only
13 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Needs extra due diligence; demand valuation comfort and recent improvement.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
68
acceptable · holding, pledge, alignment
Cash flow
28
weak · profit to cash conversion
Balance sheet
88
strong · leverage and solvency
Discipline
52
watch · capital discipline
Results
39
weak · quarterly consistency
Trust positives
- ▸Promoter holding is 60.2%.
- ▸Promoter pledge is zero.
- ▸Debt/equity is 0.00.
- ▸4/4 latest quarters had positive YoY revenue growth.
Trust risks
- ▸Promoter holding fell 5.8%.
- ▸Operating cash flow is negative at ₹-25 Cr.
- ▸2 latest quarters had PAT decline worse than 25% YoY.
- ▸Only 0 years of positive FCF.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Vasa Denticity Ltd.
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Concall transcriptAug 2026
Aug 2026 · Transcript
Source: Nse
Investor presentationAug 2026
Aug 2026 · PPT
Source: Nse
Concall transcriptJun 2026
Jun 2026 · Transcript
Source: Company Ir
Investor presentationMay 2026
May 2026 · Investor Presentation 26 May 2026 - Vasa Denticity shared Q4/FY26 investor presentation with audited results; FY26 total income ₹283.39 Cr, EBITDA ₹15.43 Cr.
Source: Nse
Annual report
Annual Report 2026
Source: Nse
Concall transcriptNov 2025
Nov 2025 · Transcript
Source: Nse
Investor presentationNov 2025
Nov 2025 · PPT
Source: Nse
Investor presentationAug 2025
Aug 2025 · PPT
Source: Nse
Concall transcriptMay 2025
May 2025 · Transcript
Source: Nse
Investor presentationMay 2025
May 2025 · PPT
Source: Nse
Annual report
Annual Report 2025
Source: Nse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.